Review





Similar Products

bmp 9  (MedChemExpress)
93
MedChemExpress bmp 9
Bmp 9, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bmp 9/product/MedChemExpress
Average 93 stars, based on 1 article reviews
bmp 9 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
bmp10  (R&D Systems)
93
R&D Systems bmp10
EC-specific overactivation of mTORC1 reduces incidence and thickness of AVMs induced by blocking antibodies. A . Time scheme for administration of tamoxifen, BMP9/10 blocking antibodies (bAbs)/Isotype <t>IgG,</t> and sample collection. B . Representative pictures showing retinal vasculatures of control (Cre-) and Tsc1 iECKO mice treated with IgGs or anti-BMP9/10 antibodies (Abs). Arrows indicate AVMs. C . Quantification of number of AVMs per retina of Control ( n = 5 mice) and Tsc1 iECKO ( n = 5 mice) mice treated with anti-BMP9/10 Abs. D . Quantification of AVM thickness in Control ( n = 5 mice) and Tsc1 iECKO mice ( n = 3) treated with IgGs or anti-BMP9/10 Abs. E . Central retinal vasculatures of control (Cre-) and Tsc1 iECKO mice, treated with anti-BMP9/10 Abs, immunolabelled for CD31, p-RPS6, and YFP (indicative of recombination). F . Quantification of the ratio of the p-RPS6 + area within the CD31 + area to the complete CD31 + area ( F ), as well as the p-RPS6 + area outside the CD31 + area to the complete non-vascular area ( G ) of central retinas of Control ( n = 3 mice) and Tsc1 iECKO ( n = 3 mice) mice treated with anti-BMP9/10 Abs. Note the vascular specific increase of p-RPS6, indicative of EC-specific mTORC1 overactivation. All data was analysed by two-tailed unpaired t-test with Welch’s correction. Bars indicate mean ± s.d. * p < 0.05
Bmp10, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bmp10/product/R&D Systems
Average 93 stars, based on 1 article reviews
bmp10 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
bmp 9  (Proteintech)
93
Proteintech bmp 9
EC-specific overactivation of mTORC1 reduces incidence and thickness of AVMs induced by blocking antibodies. A . Time scheme for administration of tamoxifen, BMP9/10 blocking antibodies (bAbs)/Isotype <t>IgG,</t> and sample collection. B . Representative pictures showing retinal vasculatures of control (Cre-) and Tsc1 iECKO mice treated with IgGs or anti-BMP9/10 antibodies (Abs). Arrows indicate AVMs. C . Quantification of number of AVMs per retina of Control ( n = 5 mice) and Tsc1 iECKO ( n = 5 mice) mice treated with anti-BMP9/10 Abs. D . Quantification of AVM thickness in Control ( n = 5 mice) and Tsc1 iECKO mice ( n = 3) treated with IgGs or anti-BMP9/10 Abs. E . Central retinal vasculatures of control (Cre-) and Tsc1 iECKO mice, treated with anti-BMP9/10 Abs, immunolabelled for CD31, p-RPS6, and YFP (indicative of recombination). F . Quantification of the ratio of the p-RPS6 + area within the CD31 + area to the complete CD31 + area ( F ), as well as the p-RPS6 + area outside the CD31 + area to the complete non-vascular area ( G ) of central retinas of Control ( n = 3 mice) and Tsc1 iECKO ( n = 3 mice) mice treated with anti-BMP9/10 Abs. Note the vascular specific increase of p-RPS6, indicative of EC-specific mTORC1 overactivation. All data was analysed by two-tailed unpaired t-test with Welch’s correction. Bars indicate mean ± s.d. * p < 0.05
Bmp 9, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bmp 9/product/Proteintech
Average 93 stars, based on 1 article reviews
bmp 9 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
recombinant gdf-2 (bmp-9)  (PeproTech)
90
PeproTech recombinant gdf-2 (bmp-9)
EC-specific overactivation of mTORC1 reduces incidence and thickness of AVMs induced by blocking antibodies. A . Time scheme for administration of tamoxifen, BMP9/10 blocking antibodies (bAbs)/Isotype <t>IgG,</t> and sample collection. B . Representative pictures showing retinal vasculatures of control (Cre-) and Tsc1 iECKO mice treated with IgGs or anti-BMP9/10 antibodies (Abs). Arrows indicate AVMs. C . Quantification of number of AVMs per retina of Control ( n = 5 mice) and Tsc1 iECKO ( n = 5 mice) mice treated with anti-BMP9/10 Abs. D . Quantification of AVM thickness in Control ( n = 5 mice) and Tsc1 iECKO mice ( n = 3) treated with IgGs or anti-BMP9/10 Abs. E . Central retinal vasculatures of control (Cre-) and Tsc1 iECKO mice, treated with anti-BMP9/10 Abs, immunolabelled for CD31, p-RPS6, and YFP (indicative of recombination). F . Quantification of the ratio of the p-RPS6 + area within the CD31 + area to the complete CD31 + area ( F ), as well as the p-RPS6 + area outside the CD31 + area to the complete non-vascular area ( G ) of central retinas of Control ( n = 3 mice) and Tsc1 iECKO ( n = 3 mice) mice treated with anti-BMP9/10 Abs. Note the vascular specific increase of p-RPS6, indicative of EC-specific mTORC1 overactivation. All data was analysed by two-tailed unpaired t-test with Welch’s correction. Bars indicate mean ± s.d. * p < 0.05
Recombinant Gdf 2 (Bmp 9), supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant gdf-2 (bmp-9)/product/PeproTech
Average 90 stars, based on 1 article reviews
recombinant gdf-2 (bmp-9) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
bmp-9 mutant  (Micromass UK Limited)
90
Micromass UK Limited bmp-9 mutant
EC-specific overactivation of mTORC1 reduces incidence and thickness of AVMs induced by blocking antibodies. A . Time scheme for administration of tamoxifen, BMP9/10 blocking antibodies (bAbs)/Isotype <t>IgG,</t> and sample collection. B . Representative pictures showing retinal vasculatures of control (Cre-) and Tsc1 iECKO mice treated with IgGs or anti-BMP9/10 antibodies (Abs). Arrows indicate AVMs. C . Quantification of number of AVMs per retina of Control ( n = 5 mice) and Tsc1 iECKO ( n = 5 mice) mice treated with anti-BMP9/10 Abs. D . Quantification of AVM thickness in Control ( n = 5 mice) and Tsc1 iECKO mice ( n = 3) treated with IgGs or anti-BMP9/10 Abs. E . Central retinal vasculatures of control (Cre-) and Tsc1 iECKO mice, treated with anti-BMP9/10 Abs, immunolabelled for CD31, p-RPS6, and YFP (indicative of recombination). F . Quantification of the ratio of the p-RPS6 + area within the CD31 + area to the complete CD31 + area ( F ), as well as the p-RPS6 + area outside the CD31 + area to the complete non-vascular area ( G ) of central retinas of Control ( n = 3 mice) and Tsc1 iECKO ( n = 3 mice) mice treated with anti-BMP9/10 Abs. Note the vascular specific increase of p-RPS6, indicative of EC-specific mTORC1 overactivation. All data was analysed by two-tailed unpaired t-test with Welch’s correction. Bars indicate mean ± s.d. * p < 0.05
Bmp 9 Mutant, supplied by Micromass UK Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bmp-9 mutant/product/Micromass UK Limited
Average 90 stars, based on 1 article reviews
bmp-9 mutant - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
bmp9  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology bmp9
EC-specific overactivation of mTORC1 reduces incidence and thickness of AVMs induced by blocking antibodies. A . Time scheme for administration of tamoxifen, BMP9/10 blocking antibodies (bAbs)/Isotype <t>IgG,</t> and sample collection. B . Representative pictures showing retinal vasculatures of control (Cre-) and Tsc1 iECKO mice treated with IgGs or anti-BMP9/10 antibodies (Abs). Arrows indicate AVMs. C . Quantification of number of AVMs per retina of Control ( n = 5 mice) and Tsc1 iECKO ( n = 5 mice) mice treated with anti-BMP9/10 Abs. D . Quantification of AVM thickness in Control ( n = 5 mice) and Tsc1 iECKO mice ( n = 3) treated with IgGs or anti-BMP9/10 Abs. E . Central retinal vasculatures of control (Cre-) and Tsc1 iECKO mice, treated with anti-BMP9/10 Abs, immunolabelled for CD31, p-RPS6, and YFP (indicative of recombination). F . Quantification of the ratio of the p-RPS6 + area within the CD31 + area to the complete CD31 + area ( F ), as well as the p-RPS6 + area outside the CD31 + area to the complete non-vascular area ( G ) of central retinas of Control ( n = 3 mice) and Tsc1 iECKO ( n = 3 mice) mice treated with anti-BMP9/10 Abs. Note the vascular specific increase of p-RPS6, indicative of EC-specific mTORC1 overactivation. All data was analysed by two-tailed unpaired t-test with Welch’s correction. Bars indicate mean ± s.d. * p < 0.05
Bmp9, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bmp9/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
bmp9 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
bmp-9 120-07  (PeproTech)
90
PeproTech bmp-9 120-07
EC-specific overactivation of mTORC1 reduces incidence and thickness of AVMs induced by blocking antibodies. A . Time scheme for administration of tamoxifen, BMP9/10 blocking antibodies (bAbs)/Isotype <t>IgG,</t> and sample collection. B . Representative pictures showing retinal vasculatures of control (Cre-) and Tsc1 iECKO mice treated with IgGs or anti-BMP9/10 antibodies (Abs). Arrows indicate AVMs. C . Quantification of number of AVMs per retina of Control ( n = 5 mice) and Tsc1 iECKO ( n = 5 mice) mice treated with anti-BMP9/10 Abs. D . Quantification of AVM thickness in Control ( n = 5 mice) and Tsc1 iECKO mice ( n = 3) treated with IgGs or anti-BMP9/10 Abs. E . Central retinal vasculatures of control (Cre-) and Tsc1 iECKO mice, treated with anti-BMP9/10 Abs, immunolabelled for CD31, p-RPS6, and YFP (indicative of recombination). F . Quantification of the ratio of the p-RPS6 + area within the CD31 + area to the complete CD31 + area ( F ), as well as the p-RPS6 + area outside the CD31 + area to the complete non-vascular area ( G ) of central retinas of Control ( n = 3 mice) and Tsc1 iECKO ( n = 3 mice) mice treated with anti-BMP9/10 Abs. Note the vascular specific increase of p-RPS6, indicative of EC-specific mTORC1 overactivation. All data was analysed by two-tailed unpaired t-test with Welch’s correction. Bars indicate mean ± s.d. * p < 0.05
Bmp 9 120 07, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bmp-9 120-07/product/PeproTech
Average 90 stars, based on 1 article reviews
bmp-9 120-07 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
bmp-9 growth factor  (Angiocrine)
90
Angiocrine bmp-9 growth factor
EC-specific overactivation of mTORC1 reduces incidence and thickness of AVMs induced by blocking antibodies. A . Time scheme for administration of tamoxifen, BMP9/10 blocking antibodies (bAbs)/Isotype <t>IgG,</t> and sample collection. B . Representative pictures showing retinal vasculatures of control (Cre-) and Tsc1 iECKO mice treated with IgGs or anti-BMP9/10 antibodies (Abs). Arrows indicate AVMs. C . Quantification of number of AVMs per retina of Control ( n = 5 mice) and Tsc1 iECKO ( n = 5 mice) mice treated with anti-BMP9/10 Abs. D . Quantification of AVM thickness in Control ( n = 5 mice) and Tsc1 iECKO mice ( n = 3) treated with IgGs or anti-BMP9/10 Abs. E . Central retinal vasculatures of control (Cre-) and Tsc1 iECKO mice, treated with anti-BMP9/10 Abs, immunolabelled for CD31, p-RPS6, and YFP (indicative of recombination). F . Quantification of the ratio of the p-RPS6 + area within the CD31 + area to the complete CD31 + area ( F ), as well as the p-RPS6 + area outside the CD31 + area to the complete non-vascular area ( G ) of central retinas of Control ( n = 3 mice) and Tsc1 iECKO ( n = 3 mice) mice treated with anti-BMP9/10 Abs. Note the vascular specific increase of p-RPS6, indicative of EC-specific mTORC1 overactivation. All data was analysed by two-tailed unpaired t-test with Welch’s correction. Bars indicate mean ± s.d. * p < 0.05
Bmp 9 Growth Factor, supplied by Angiocrine, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bmp-9 growth factor/product/Angiocrine
Average 90 stars, based on 1 article reviews
bmp-9 growth factor - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti bmp 9  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology anti bmp 9
EC-specific overactivation of mTORC1 reduces incidence and thickness of AVMs induced by blocking antibodies. A . Time scheme for administration of tamoxifen, BMP9/10 blocking antibodies (bAbs)/Isotype <t>IgG,</t> and sample collection. B . Representative pictures showing retinal vasculatures of control (Cre-) and Tsc1 iECKO mice treated with IgGs or anti-BMP9/10 antibodies (Abs). Arrows indicate AVMs. C . Quantification of number of AVMs per retina of Control ( n = 5 mice) and Tsc1 iECKO ( n = 5 mice) mice treated with anti-BMP9/10 Abs. D . Quantification of AVM thickness in Control ( n = 5 mice) and Tsc1 iECKO mice ( n = 3) treated with IgGs or anti-BMP9/10 Abs. E . Central retinal vasculatures of control (Cre-) and Tsc1 iECKO mice, treated with anti-BMP9/10 Abs, immunolabelled for CD31, p-RPS6, and YFP (indicative of recombination). F . Quantification of the ratio of the p-RPS6 + area within the CD31 + area to the complete CD31 + area ( F ), as well as the p-RPS6 + area outside the CD31 + area to the complete non-vascular area ( G ) of central retinas of Control ( n = 3 mice) and Tsc1 iECKO ( n = 3 mice) mice treated with anti-BMP9/10 Abs. Note the vascular specific increase of p-RPS6, indicative of EC-specific mTORC1 overactivation. All data was analysed by two-tailed unpaired t-test with Welch’s correction. Bars indicate mean ± s.d. * p < 0.05
Anti Bmp 9, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti bmp 9/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
anti bmp 9 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


EC-specific overactivation of mTORC1 reduces incidence and thickness of AVMs induced by blocking antibodies. A . Time scheme for administration of tamoxifen, BMP9/10 blocking antibodies (bAbs)/Isotype IgG, and sample collection. B . Representative pictures showing retinal vasculatures of control (Cre-) and Tsc1 iECKO mice treated with IgGs or anti-BMP9/10 antibodies (Abs). Arrows indicate AVMs. C . Quantification of number of AVMs per retina of Control ( n = 5 mice) and Tsc1 iECKO ( n = 5 mice) mice treated with anti-BMP9/10 Abs. D . Quantification of AVM thickness in Control ( n = 5 mice) and Tsc1 iECKO mice ( n = 3) treated with IgGs or anti-BMP9/10 Abs. E . Central retinal vasculatures of control (Cre-) and Tsc1 iECKO mice, treated with anti-BMP9/10 Abs, immunolabelled for CD31, p-RPS6, and YFP (indicative of recombination). F . Quantification of the ratio of the p-RPS6 + area within the CD31 + area to the complete CD31 + area ( F ), as well as the p-RPS6 + area outside the CD31 + area to the complete non-vascular area ( G ) of central retinas of Control ( n = 3 mice) and Tsc1 iECKO ( n = 3 mice) mice treated with anti-BMP9/10 Abs. Note the vascular specific increase of p-RPS6, indicative of EC-specific mTORC1 overactivation. All data was analysed by two-tailed unpaired t-test with Welch’s correction. Bars indicate mean ± s.d. * p < 0.05

Journal: Angiogenesis

Article Title: Genetic and pharmacological targeting of mTORC1 in mouse models of arteriovenous malformation expose non-cell autonomous signalling in HHT

doi: 10.1007/s10456-024-09961-5

Figure Lengend Snippet: EC-specific overactivation of mTORC1 reduces incidence and thickness of AVMs induced by blocking antibodies. A . Time scheme for administration of tamoxifen, BMP9/10 blocking antibodies (bAbs)/Isotype IgG, and sample collection. B . Representative pictures showing retinal vasculatures of control (Cre-) and Tsc1 iECKO mice treated with IgGs or anti-BMP9/10 antibodies (Abs). Arrows indicate AVMs. C . Quantification of number of AVMs per retina of Control ( n = 5 mice) and Tsc1 iECKO ( n = 5 mice) mice treated with anti-BMP9/10 Abs. D . Quantification of AVM thickness in Control ( n = 5 mice) and Tsc1 iECKO mice ( n = 3) treated with IgGs or anti-BMP9/10 Abs. E . Central retinal vasculatures of control (Cre-) and Tsc1 iECKO mice, treated with anti-BMP9/10 Abs, immunolabelled for CD31, p-RPS6, and YFP (indicative of recombination). F . Quantification of the ratio of the p-RPS6 + area within the CD31 + area to the complete CD31 + area ( F ), as well as the p-RPS6 + area outside the CD31 + area to the complete non-vascular area ( G ) of central retinas of Control ( n = 3 mice) and Tsc1 iECKO ( n = 3 mice) mice treated with anti-BMP9/10 Abs. Note the vascular specific increase of p-RPS6, indicative of EC-specific mTORC1 overactivation. All data was analysed by two-tailed unpaired t-test with Welch’s correction. Bars indicate mean ± s.d. * p < 0.05

Article Snippet: Pups were treated with mouse monoclonal antibodies against BMP9 and BMP10 (15 mg/kg, IgG2b, MAB3209; 15 mg/kg, IgG2a, MAB2926; R&D Systems, respectively) or isotype control antibodies (15 mg/kg, IgG2b, MAB004; 15 mg/kg, IgG2a, MAB003; R&D Systems, respectively) at P3, P4 and P5 and tissues were harvested at P6.

Techniques: Blocking Assay, Control, Two Tailed Test